• 英国上市公司365

    Global
    关于英国上市公司365

    致力于纳米抗体
    创新药物研发

    关于英国上市公司365
    科研论文
    截止现在，英国上市公司365生物研发团队在具有重要影响力的期刊上发表研究论文多篇。
    2024-12-03
    Efficient development of nanobody-based affinity chromatography for AAV8 purification.
    发表于:Protein Expression and Purification
    查看更多内容
    2024-10-30
    Ce-MOF@Au-Based Electrochemical Immunosensor for Apolipoprotein A1 Detection Using Nanobody Technology.
    发表于:ACS Applied Materials & Interfaces
    查看更多内容
    2024-06-11
    A novel inhalable nanobody targeting IL-4Rα for the treatment of asthma.
    发表于:J Allergy Clin Immunol.
    查看更多内容
    2024-06-10
    Nanobody-Based Microfluidic Immunosensor Chip Using Tetraphenylethylene-Derived Covalent Organic Frameworks as Aggregation-Induced Electrochemiluminescence Emitters for the Detection of Thymic Stromal Lymphopoietin.
    发表于:Analytical Chemistry
    查看更多内容
    2024-05-16
    A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer.
    发表于:Journal of Nanobiotechnology.
    查看更多内容
    2024-02-16
    High performance production process development and scale-up of ananti-TSLP nanobody
    发表于:Protein expression and purification, 218, 106441.
    查看更多内容
    总计 24 1234